Kamada (KMDA)

Sep 25, 2026

Amir London, CEO of Kamada (NASDAQ: KMDA), acquired stock options for 800,000 shares on September 25, allowing him to purchase the stock at $6.71 per share. The transaction, valued at approximately $1.80 million based on the current stock price of $8.96, signals a positive outlook from the insider. The article also provides an analysis of Kamada's financial health, including revenue growth, profitability metrics, debt management, and valuation.

Sep 25, 2026

Lilach Payorski, a Director at Kamada (NASDAQ: KMDA), acquired stock options for 60,000 shares valued at $136,577. This transaction, disclosed on September 24, allows her to purchase shares at an exercise price of $6.69 each. The article also provides a detailed financial overview of Kamada, highlighting its revenue growth, profitability, debt management, and market valuation.

Sep 25, 2026

Boris Gorelik, VP at Kamada (NASDAQ: KMDA), exercised stock options for 0 shares of KMDA, resulting in a transaction value of $0, as disclosed in an SEC filing on September 24. This occurred while Kamada shares were down 0.91% and trading at $8.96. The article also provides a financial overview of Kamada, highlighting its revenue growth, gross margin, EPS, debt management, and valuation metrics.

Sep 25, 2026

KAMADA LTD (NASDAQ: KMDA), a biotechnology company, awarded 86,500 derivative securities to director Goldwasser Karnit on August 27, 2026, at a price of $0 per share. Following these three transactions, which were reported under SEC transaction code A, Goldwasser Karnit's post-transaction holding of derivative securities is 30,000. The article highlights the distinction between the awarded amount and the director's total derivative security ownership.

Sep 24, 2026

Assaf Itshayek, a Director at Kamada (NASDAQ: KMDA), acquired 46,000 stock options with an exercise price of $6.93 per share, valued at $80,739. This insider transaction highlights a positive sentiment towards the company. Kamada, a plasma-derived protein therapeutics company, reported a 22.72% revenue growth but faces challenges with a low gross margin and high debt-to-equity ratio.

Sep 24, 2026

Kamada's CFO, Chaime Orlev, acquired 202,500 company stock options valued at $413,774, according to a recent SEC filing. The options allow Orlev to purchase shares at $6.65 each, indicating confidence in the Health Care sector company. The article also provides a financial overview of Kamada, detailing its revenue growth, gross margin, EPS, debt management, and various valuation ratios.

Sep 24, 2026

Nir Livneh, VP at Kamada (NASDAQ: KMDA), recently acquired stock options for 89,485 shares, valued at $171,121 based on current trading prices. Kamada is a drug-focused company specializing in plasma-derived protein therapeutics, reporting a 22.72% revenue growth but facing challenges with a low gross margin and high debt-to-equity ratio. The article highlights the importance of insider transactions as an indicator of positive expectations, while also discussing Kamada's financial metrics and valuation.

Sep 24, 2026

Leon Recanati, a Board Member at Kamada (NASDAQ: KMDA), recently acquired stock options for 86,500 shares, valued at $154,219, with an exercise price of $6.91 per share. This strategic move was disclosed in a September 23 SEC filing. The article also provides a financial overview of Kamada, highlighting its revenue growth, gross margin, EPS, debt management, and valuation metrics, while emphasizing the importance of insider transactions as indicators of future stock performance.

Sep 24, 2026

Eran Nir, VP at Kamada (NASDAQ: KMDA), has acquired stock options for 112,500 shares, valued at $173,474. The options allow him to buy shares at an exercise price of $7.15 per share, indicating a strategic derivative acquisition. Kamada, a plasma-derived protein therapeutics company, shows strong revenue growth but faces challenges in gross margin, debt management, and higher-than-average valuation ratios.

Sep 17, 2026

Yael Brenner, VP of Quality at Kamada Ltd (NASDAQ:KMDA), executed five net employee stock option grants on September 14, 2026. These transactions, detailed in a Form 4 filing on September 17, 2026, resulted in Brenner directly holding 6,266 ordinary shares. The options were exercised at $5.93 per share, with shares withheld to cover exercise costs and taxes, and no derivative securities remain beneficially owned.

Sep 16, 2026

Kamada Ltd Director David Tsur recently sold 177,173 shares of the company, bringing his direct ownership to 430,756 shares. This transaction is the only insider selling activity over the past year, aligning with a trend of institutional investors also trimming their positions. Despite the insider selling, Kamada Ltd is considered "Fairly Valued" based on GuruFocus's GF Value, with its stock trading at $8.26, resulting in a market cap of $465.77 million.

Sep 14, 2026

KAMADA (NASDAQ: KMDA) Director Tsur David sold a total of 177,173 shares in three separate transactions between September 7 and September 9, 2026. The shares were sold at prices ranging from $8.26 to $8.28 per share. Following these sales, David's remaining stake in KAMADA stands at 430,756 shares.